Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

ElMindA obtains FDA approval for BNA Analysis System

Israel-based ElMindA has obtained approval from the US Food and Drug Administration (FDA) for its Brain Network Activity (BNA) analysis system for the assessment of brain function.

The FDA has currently approved the BNA Analysis System for 14 to 24 year-olds and the company said that it is conducting additional research to further expand the indicated age group.

Combining non-invasive, multi-channel EEG technology with signal processing and analysis algorithms, the BNA Analysis System measures patterns of brain networks activated during specific brain processes and deliver both quantitative and qualitative insights into brain functionality.

The advanced brain analysis and mapping technology enables assessment of brain health based on objective neuro-physiological measures.

Healthcare providers can evaluate a patient’s functional brain network activity based on BNA output and compare the activity with functional network activity of healthy brains, the company said.

ElMindA CEO Ronen Gadot said: "Greater understanding of how our brain processes information, how it gets its job done, ultimately holds the potential to improve brain health and disease management over a person’s lifetime.

"BNA adds an objective layer of information to clinical symptom assessments and neurocognitive tests, providing clinicians with a comprehensive view of brain health."

ElMindA has developed a growing database of brain activity from both healthy subjects and patients with brain-related disorders.

The database currently includes more than 7,000 BNA datasets, which provide a clinically supported foundation to potentially help identify and manage neurological disorders such as attention deficit hyperactivity disorder or pain, and brain injuries such as concussion.